Eudaimonia Partners, LLC Genmab A/S Transaction History

Eudaimonia Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$32.88 - $44.57 $13,710 - $18,585	-417 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$30.92 - $44.4 $2,659 - $3,818	-86 Reduced 17.1%	417 $14,000
Q4 2020 Feb 18, 2021	SELL	$33.66 - $40.76 $2,894 - $3,505	-86 Reduced 14.6%	503 $20,000
Q3 2020 Nov 23, 2020	SELL	$33.07 - $38.68 $9,193 - $10,753	-278 Reduced 32.06%	589 $22,000
Q3 2020 Nov 16, 2020	BUY	$33.07 - $38.68 $9,193 - $10,753	278 Added 47.2%	867 $26,000
Q2 2020 Aug 14, 2020	BUY	$20.05 - $33.89 $11,809 - $19,961	589 New	589 $20,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Eudaimonia Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Eudaimonia Partners, LLC with notifications on news.